Table 1.

Characteristics of 9 Studies14, 15, 16, 17, 18, 19, 20, 21, 22 Included for the Estimation of the Rate of IE After TPVI

Study, Year of Publication	Country	Period of Patient Enrollment	No. of Patients	Follow‐Up, mo	Patient‐Years of Follow‐Up	Age, ya	Male Sex, %	TOF, %	TA, %	AS (S/P Ross Procedure), %	Homograft, %	Prestenting, %	IE cummulative Incidence, %	IE Incidence Rate/Patient‐Year, %
Biernacka et al,20 2015	Poland	2008–2012	26	20.4	44	NA	NA	NA	NA	NA	NA	100.0	15.4	9.1
O'Donnell et al,18 2016	New Zealand	2009–2015	25	35	73	18 (11–51)	60.0	64.0	24.0	12.0	92.0	96.0	16.0	5.5
Cheung et al,21 2013	Denmark	2006–2012	42	27	95	25 (6–67)	NA	NA	NA	NA	NA	NA	14.3	6.3
Hascoet et al,22 2017	France	2008–2014	31	58.8	151.9	19 (15.8–28.9)b	53.0	81.0		9.0	25.0	91.0	25.0	5.3
Butera et al,17 2013	Italy	2007–2010	61	30	153	24 (11–65)	52.0	44.0	8.0	15.0	54.0	87.0	3.2	1.3
Malekzadeh‐Milani et al,16 2014	France	2009–2013	93	23.8	184	20.1 (18.2–21.8)	56.0	26.0	12.0	14.0	20.0	NA	8.6	4.4
Van Dijck et al,19 2015	Belgium	2006–2013	107	24	214	14.3 (4.5–80.5)	66.0	52.0	7.0	19.0	57.0	NA	7.5	3.7
Lurz et al,15 2008	UK‐France	2000–2007	155	28.4	367	21.2 (7–71)	58.0	61.0	11.0	8.0	81.0	NA	3.2	1.4
McElhinney et al,14 2013	United States, Canada, and Europe	2007–2012	311	30	778	18.2 (5–59)	NA	44.0		18.0	70.0	73.0	5.1	2.1
Total	…	2000–2015	851	30.8	2059.9	20.0	57.5	48.5	12.4	13.6	57.0	89.4	10.92	4.33

AS indicates aortic stenosis; IE, infective endocarditis; NA, not applicable; RVOT, right ventricular outflow tract; S/P, status post; TA, truncus arteriosus; TOF, tetralogy of Fallot; TPVI, transcatheter pulmonary valve implantation.

^aAverage (range).

^bMedian (interquartile range).